Search Results - "Mannaerts, BMJL"

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol by Devroey, P., Boostanfar, R., Koper, N.P., Mannaerts, B.M.J.L., IJzerman-Boon, P.C., Fauser, B.C.J.M.

“…BACKGROUND Corifollitropin alfa, a fusion protein lacking LH activity, has a longer elimination half-life and extended time to peak levels than recombinant FSH…”
Get full text

Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency by Fauser, B.C.J.M., Mannaerts, B.M.J.L., Devroey, P., Leader, A., Boime, I., Baird, D.T.

“…BACKGROUND Recombinant DNA technologies have been used to develop longer-acting therapeutic proteins. One approach is to introduce sequences containing…”
Get full text

Dose Selection of Corifollitropin Alfa by Modeling and Simulation in Controlled Ovarian Stimulation by Greef, R, Zandvliet, A S, Haan, A F J, IJzerman‐Boon, P C, Marintcheva‐Petrova, M, Mannaerts, B M J L

“…In controlled ovarian stimulation (COS), a single subcutaneous dose of corifollitropin alfa is used to initiate and sustain multifollicular growth for 7 days…”
Get full text

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers by Oberyé, J J, Mannaerts, B M, Huisman, J A, Timmer, C J

“…To assess the dose-proportionality and pharmacodynamic properties of multiple doses of ganirelix (Antagon/Orgalutran; NV Organon, Oss, the Netherlands)…”
Get more information

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers by Oberyé, J J, Mannaerts, B M, Kleijn, H J, Timmer, C J

“…To assess the absolute bioavailability of ganirelix (Antagon/Orgalutran; NV Organon, Oss, the Netherlands) after a single SC injection. Randomized, crossover,…”
Get more information

Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins by Out, H J, Driessen, S G, Mannaerts, B M, Coelingh Bennink, H J

“…To assess ongoing pregnancy rates (PRs) in IVF after treatment with recombinant FSH (follitropin beta, Puregon; NV Organon, Oss, The Netherlands) as compared…”
Get more information

Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency by Schoot, D C, Coelingh Bennink, H J, Mannaerts, B M, Lamberts, S W, Bouchard, P, Fauser, B C

“…To evaluate the importance of luteinizing hormone (LH) for normal estrogen production and subsequent development of ovarian follicles, a woman with isolated…”
Get more information

Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon) by de Jong, D, Macklon, N S, Eijkemans, M J, Mannaerts, B M, Coelingh Bennink, H J, Fauser, B C

“…To investigate relations between dose of GnRH antagonist and follicular phase characteristics. Randomized controlled multicenter trial. Tertiary referral…”
Get more information

Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix by Boerrigter, Peter J., de Bie, Joris J., Mannaerts, Bernadette M.J.L., van Leeuwen, Bert P., Passier-Timmermans, Dorrie P.J.

“…BACKGROUND: To establish long-term safety, follow-up data on pregnancy, birth and neonatal outcome were collected during clinical development trials with…”
Get full text

A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim/Puregon) in healthy female volunteers by Voortman, G, Mannaerts, B M, Huisman, J A

“…To assess pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous (s.c.) administration of recombinant FSH in comparison with the intramuscular (i.m.)…”
Get more information

Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies by Out, HJ, Mannaerts, BMJL, Driessen, SGAJ, Bennink, HJTC

“…The clinical assessment of recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction technologies such as in-vitro fertilization (IVF)…”
Get full text

Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy by Mannaerts, BMJL, Rombout, F, Out, HJ, Bennink, HC

“…Single-dose and multiple-rising dose studies of recombinant follicle stimulating hormone (rFSH) in hypogonadotrophic male and female volunteers demonstrated…”
Get full text

High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization by de Jong, D, Macklon, N S, Mannaerts, B M, Coelingh Bennink, H J, Fauser, B C

“…This case report describes the first attempt to treat imminent ovarian hyperstimulation syndrome (OHSS) by using a gonadotrophin-releasing hormone (GnRH)…”
Get full text

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration by Mannaerts, B M, Geurts, T B, Odink, J

“…The objective of this study was to compare the bioavailability of s.c. and i.m. administration of human chorionic gonadotrophin (HCG; Pregnyl). In a…”
Get full text

Consistency of gonadotrophin products by Gordon, Keith, Mulders, John WM, van Hooren, Eric, van den Hooven, Henno, Oddens, Björn J, Mannaerts, Bernadette MJL

Get full text

Consistency of gonadotrophin products – further comment by Gordon, Keith, Mulders, John WM, van Hooren, Eric, Hooven, Henno van den, Oddens, Björn J, Verbon, Frans, Mannaerts, Bernadette MJL

Get full text

Follitropin-β administered by pen device has superior local tolerance compared with follitropin-α administered by conventional syringe by Craenmehr, E, Bontje, PM, Hoomans, E, Voortman, G, Mannaerts, BMJL

“…A receiver- and assessor-blind, randomized, single-centre, crossover study was performed in 60 healthy women volunteers, to compare the local tolerance of two…”
Get full text

LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome by Hohmann, F P, Laven, J S E, Mulders, A G M G J, Oberyé, J J L, Mannaerts, B M J L, de Jong, F H, Fauser, B C J M

“…Elevated LH concentration is a common feature in polycystic ovary syndrome (PCOS). This study was designed to establish whether elevated LH levels in PCOS…”
Get full text

Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI using a gnrh antagonist (orgalutran/antagon) to prevent a premature LH surge : A case report by DE JONG, Diederick, VAN HOOREN, Eric G, MACKLON, Nicholas S, MANNAERTS, Bernadette M. J. L, FAUSER, Bart C. J. M

Get full text

Sister chromatid exchanges in calves with hereditary zinc deficiency (lethal trait A 46) by Bosma, A A, Mannaerts, B M, de Haan, N A, Kroneman, J

“…Frequencies of sister chromatid exchanges (SCEs) in cultured blood lymphocytes are rather lower than higher in calves with hereditary zinc deficiency (lethal…”
Get more information